Screening for HIV infection: A healthy,,"low-risk" 42-year-old man

JAMA

Volumn 306, Issue 6, 2011, Pages 637-644

  Libman, Howard ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; HIGH RISK POPULATION; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; PATIENT COUNSELING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCREENING TEST; SEXUAL BEHAVIOR; ADULT; ARTICLE; ATTITUDE TO HEALTH; CASE REPORT; CLINICAL OBSERVATION; CLINICAL STUDY; COST BENEFIT ANALYSIS; COUNSELING; DECISION MAKING; DIAGNOSIS; DISEASE TRANSMISSION; DOCTOR PATIENT RELATION; IMMUNOASSAY; INFORMED CONSENT; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; PRIMARY HEALTH CARE; PUBLIC HEALTH SERVICE; RISK; UNITED STATES;

ADULT; ATTITUDE TO HEALTH; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COST-BENEFIT ANALYSIS; COUNSELING; DECISION MAKING; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS; IMMUNOASSAY; INFORMED CONSENT; MALE; PATIENT COMPLIANCE; PHYSICIAN-PATIENT RELATIONS; PREVALENCE; PRIMARY HEALTH CARE; RISK; SEXUAL BEHAVIOR; UNITED STATES;

EID: 80051563235     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1016     Document Type: Conference Paper

References (72)

1. Hall HI, Song R, Rhodes P, et al HIV Incidence Surveillance Group. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-529.
2. Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010;53(5):619-624.
3. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20(10):1447-1450. (Pubitemid 43948252)
4. Cassels S, Menza TW, Goodreau SM, Golden MR. HIV serosorting as a harm reduction strategy: evidence from Seattle, Washington. AIDS. 2009;23(18):2497-2506.
5. Wilson DP, Regan DG, Heymer KJ, Jin F, Prestage GP, Grulich AE. Serosorting may increase the risk of HIV acquisition among men who have sex with men. Sex Transm Dis. 2010;37(1):13-17.
6. Centers for Disease Control and Prevention. Diagnoses of HIV infection and AIDS in the United States and dependent areas, 2009. http://www.cdc.gov/hiv/ surveillance/resources/reports/2009report. Accessed March 2, 2011.
7. Centers for Disease Control and Prevention. Prevalence and awareness of HIV infection among men who have sex with men - 21 cities, United States, 2008. MMWR Morb Mortal Wkly Rep. 2010;59(37):1201-1207.
8. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ. 1992;304(6830):809-813.
9. Leynaert B, Downs AM, De Vincenzi I; European Study Group on Heterosexual Transmission of HIV. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. Am J Epidemiol. 1998;148(1):88-96. (Pubitemid 28317549)
10. Varghese B, Maher JE, Peterman TA, Branson BM, Steketee RW. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis. 2002;29(1):38-43. (Pubitemid 34074430)
11. World Health Organization. Principles and Practice of Screening for Disease. Geneva, Switzerland: World Health Organization; 1968.
12. Walensky RP, Weinstein MC, Kimmel AD, et al. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005;118(3):292-300. (Pubitemid 40312641)
13. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570-585. (Pubitemid 40204670)
14. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586-595. (Pubitemid 40204671)
15. Paltiel AD, Walensky RP, Schackman BR, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145(11):797-806. (Pubitemid 351650333)
16. Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med. 2008;148(12):889-903. (Pubitemid 351860821)
17. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep. 2001;50(RR-19):1-57.
18. Wenrich MD, Curtis JR, Carline JD, Paauw DS, Ramsey PG. HIV risk screening in the primary care setting: assessment of physicians' skills. J Gen Intern Med. 1997;12(2):107-113. (Pubitemid 27131232)
19. Epstein RM, Morse DS, Frankel RM, Frarey L, Anderson K, Beckman HB. Awkward moments in patient-physician communication about HIV risk. Ann Intern Med. 1998;128(6):435-442. (Pubitemid 28128703)
20. Bernstein KT, Liu KL, Begier EM, Koblin B, Karpati A, Murrill C. Same-sex attraction disclosure to health care providers among New York City men who have sex with men: implications for HIV testing approaches. Arch Intern Med. 2008;168(13):1458-1464. (Pubitemid 352008427)
21. Ostermann J, Kumar V, Pence BW, Whetten K. Trends in HIV testing and differences between planned and actual testing in the United States, 2000-2005. Arch Intern Med. 2007;167(19):2128-2135. (Pubitemid 350041622)
22. Centers for Disease Control and Prevention. Revised recommendations for HIV screening of pregnant women. MMWR Recomm Rep. 2001;50(RR-19):63-85.
23. Branson BM, Handsfield HH, Lampe MA, et al Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17.
24. Centers for Disease Control and Prevention. Act Against AIDS campaign. http://www.actagainstaids.org/provider/hssc/index.html. Accessed July 2, 2011.
25. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Owens DK; Clinical Efficacy Assessment Subcommittee, American College of Physicians. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med. 2009;150(2):125-131.
26. US Preventive Services Task Force. Screening for HIV. July 2005. http://www.uspreventiveservicestaskforce.org/uspstf/uspshivi.htm. Accessed September 20, 2010.
27. Chou R, Huffman LH, Fu R, Smits AK, Korthuis PT; US Preventive Services Task Force. Screening for HIV: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2005;143(1):55-73.
28. World Health Organization. Guidance on Provider-Initiated HIV Testing and Counselling in Health Facilities. 2007. http://www.who.int/hiv/pub/guidelines/ 9789241595568-en.pdf. Accessed July 14, 2011.
29. Centers for Disease Control and Prevention. Late vs early testing of HIV - 16 sites, United States, 2000-2003. MMWR Morb Mortal Wkly Rep. 2003;52(25):581-586.
30. Centers for Disease Control and Prevention. Vital signs: HIV testing and diagnosis among adults - United States, 2001-2009. MMWR Morb Mortal Wkly Rep. 2010;59(47):1550-1555.
31. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39(4):446-453. (Pubitemid 41003791)
32. Holtgrave DR, Anderson T. Utilizing HIV transmission rates to assist in prioritizing HIV prevention services. Int J STD AIDS. 2004;15(12):789-792. (Pubitemid 40018701)
33. Holtgrave DR, Pinkerton SD. Can increasing awareness of HIV seropositivity reduce infections by 50% in the United States? J Acquir Immune Defic Syndr. 2007;44(3):360-363. (Pubitemid 46328356)
34. + cell strata. Ann Intern Med. 2003;138(8):620-626.
35. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. January 10, 2011. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed July 17, 2011.
36. Emery S, Neuhaus JA, Phillips AN, et al Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133-1144. (Pubitemid 351590049)
37. Kitahata MM, Gange SJ, Abraham AG, et al NA-ACCORD Investigators. Effect of early vs deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815-1826.
38. Porco TC, Martin JN, Page-Shafer KA, et al. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004;18(1):81-88. (Pubitemid 38402321)
39. Castilla J, Del Romero J, Hernando V, Marincovich B, García S, Rodríguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40(1):96-101. (Pubitemid 41233212)
40. HIV Prevention Trials Network. Initiation of antiretroviral treatment protects uninfected sexual partners from HIV infection (HPTN Study 052) [press release]. May 12, 2011. http://www.hptn.org/web%20documents/PressReleases/ HPTN052PressReleaseFINAL5-12-118am.pdf. Accessed July 16, 2011.
41. US Department of Justice. Questions and answers: the ADA and persons with HIV/AIDS. http://www.ada.gov/pubs/hivqanda.txt. Accessed March 2, 2011.
42. Aberg JA, Kaplan JE, Libman H, et al HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(5):651-681.
43. Bartlett JG. Diagnostic assays for HIV infection. Waltham, MA: UpToDate Inc; February 2010. http://www.uptodate.com/contents/diagnostic-assays-for-hiv- infection?source=search-result&selectedTitle=1%7E150. Accessed July 14, 2011.
44. Centers for Disease Control. Update: serologic testing for HIV-1 antibody - United States, 1988 and 1989. MMWR Morb Mortal Wkly Rep. 1990;39(22):380-383.
45. Farzadegan H, Vlahov D, Solomon L, et al. Detection of human immunodeficiency virus type 1 infection by polymerase chain reaction in a cohort of seronegative intravenous drug users. J Infect Dis. 1993;168(2):327-331. (Pubitemid 23210607)
46. Busch MP, Eble BE, Khayam-Bashi H, et al. Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. N Engl J Med. 1991;325(1):1-5.
47. Centers for Disease Control and Prevention. Rapid HIV testing. July 24, 2009. http://www.cdc.gov/hiv/topics/testing/rapid/. Accessed September 20, 2010.
48. US Food and Drug Administration. INSTI HIV-1 antibody test. November 30, 2010. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ ApprovedProducts/PremarketApprovalsPMAs/ucm235024.htm. Accessed March 2, 2011.
49. Martin CA, Keren DF. Comparison of murex single-use diagnostic system with traditional enzyme immunoassay for detection of exposure to human immunodeficiency virus. Clin Diagn Lab Immunol. 2002;9(1):187-189. (Pubitemid 34084299)
50. Home Access Health Corporation. The Home Access HIV-1 test system. http://www.homeaccess.com/hiv-test.asp. Accessed September 20, 2010.
51. Frank AP, Wandell MG, Headings MD, Conant MA, Woody GE, Michel C. Anonymous HIV testing using home collection and telemedicine counseling: a multicenter evaluation. Arch Intern Med. 1997;157(3):309-314. (Pubitemid 27066400)
52. US Food and Drug Administration. Abbott Architect HIV Ag/Ab combo. June 18, 2010. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ ucm216291.htm. Accessed March 2, 2011.
53. Anaya HD, Hoang T, Golden JF, et al. Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing. J Gen Intern Med. 2008;23(6):800-807.
54. Brooks L, Rietmeijer CA, McEwen D, Subiadur JA, Mettenbrink CJ. Normalizing HIV testing in a busy urban sexually transmitted infections clinic. Sex Transm Dis. 2009;36:127-128.
55. West-Ojo T, Samala R, Griffin A, et al Centers for Disease Control and Prevention. Expanded HIV testing and trends in diagnoses of HIV infection - District of Columbia, 2004-2008. MMWR Morb Mortal Wkly Rep. 2010;59(24):737-741.
56. Centers for Disease Control and Prevention. HIV testing challenges. October 30, 2006. http://www.cdc.gov/hiv/topics/testing/challenges.htm. Accessed September 20, 2010.
57. Paddock C. CDC recommendations for routine HIV testing largely ignored. November 21, 2008. http://www.medicalnewstoday.com/articles/130267.php. Accessed September 20, 2010.
58. Burke RC, Sepkowitz KA, Bernstein KT, et al. Why don't physicians test for HIV? a review of the US literature. AIDS. 2007;21(12):1617-1624. (Pubitemid 47075483)
59. Siegel M, Kennedy L, Rexroth K, et al. Better but not ideal acceptance of routine inpatient HIV point-of-care testing among veterans in a high prevalence area. J Acquir Immune Defic Syndr. 2010;55(2):205-210.
60. Haukoos JS, Hopkins E, Conroy AA, et al Denver Emergency Department HIV Opt-Out Study Group. Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients. JAMA. 2010;304(3):284-292.
61. Kaiser Family Foundation. Survey of Americans on HIV/AIDS. May 8, 2006. http://www.kff.org/kaiserpolls/pomr050806pkg.cfm. Accessed September 20, 2010.
62. Korthuis PT, Berkenblit GV, Sullivan LE, et al. General internists' beliefs, behaviors, and perceived barriers to routine HIV screening in primary care. AIDS Educ Prev. 2011;23(3)(suppl):70-83.
63. Bashook PG, Edison MI, Sullivan LE, et al. Physician barriers to implementing routine HIV testing in primary care settings: a qualitative analysis. J Gen Intern Med. 2008;23(suppl 2):367.
64. Commonwealth of Massachusetts. General laws: section 70F: HLTV-III test; confidentiality; informed consent. http://www.malegislature.gov/Laws/ GeneralLaws/PartI/TitleXVI/Chapter111/Section70F. Accessed July 16, 2010.
65. Mahajan AP, Stemple L, Shapiro MF, King JB, Cunningham WE. Consistency of state statutes with the Centers for Disease Control and Prevention HIV testing recommendations for health care settings. Ann Intern Med. 2009;150(4):263-269.
66. Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH. Optout testing for human immunodeficiency virus in the United States: progress and challenges. JAMA. 2008;300(8):945-951.
67. National HIV/AIDS Clinicians' Consultation Center. Compendium of HIV state testing laws. 2011. http://www.nccc.ucsf.edu/consultation-library/state- hiv-testing-laws. Accessed March 14, 2011.
68. Gatty B. Positives are clear but impediments exist. HIV Specialist. 2010: 10-13 Spring.
69. Zetola NM, Klausner JD, Haller B, Nassos P, Katz MH. Association between rates of HIV testing and elimination of written consents in San Francisco. JAMA. 2007;297(10):1061-1062. (Pubitemid 46425529)
70. Sontag S. AIDS and its Metaphors. New York, NY: Farrar Straus & Giroux; 1989.
71. McKinstry LA, Goldbaum GM, Meischke HW. Telephone notification of HIV test results: impact in King County, Washington. Sex Transm Dis. 2007;34(10):796-800. (Pubitemid 47463841)
72. Centers for Disease Control and Prevention. Consultation on Revised Guidelines for HIV Counseling, Testing, and Referral in Non-Health-Care Settings. September 2009. http://www.cdc.gov/hiv/topics/testing/resources/other/ consultation.htm. Accessed September 20, 2010.